ACCES TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) FOR INJECTING DRUG USERS IN THE WHO EUROPEAN REGION 2002-2004

Documenti analoghi

• WITHDRAWAL SYMPTOMS AS A PREDICTOR OF MORTALITY IN PATIENTS HIV-INFECTED THROUGH DRUG USE AND RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
  di: MICHEL, L.
• THE IMPACT OF METHADONE OR BUPRENORPHINE TREATMENT AND ONGOING INJECTION ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ADHERENCE: EVIDENCE FROM THE MANIF2000 COHORT STUDY
  di: ROUX, P.
• SOCIAL AND STRUCTURAL DETERMINANTS OF HAART ACCESS AND ADHERENCE AMONG INJECTION DRUG USERS
  di: KRUSI, A.
• METHADONE MAINTENANCE THERAPY PROMOTES INITIATION OF ANTIRETROVIRAL THERAPY AMONG INJECTION DRUG USERS
  di: UHLMANN, S.
• IMPACT OF HIV TESTING ON UPTAKE OF HIV THERAPY AMONG ANTIRETROVIRAL NAIVE HIV. INFECTED INJECTION DRUG USERS
  di: WOOD, E.